| Net Loss Per Share |
Note
13 — Net Loss Per Share
The
Net loss per share basic and diluted for the respective periods indicated is as follows:
Schedule
of Net Loss Per Share Basic and Diluted
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| Numerator | |
| | |
| | |
| | |
| |
| Net loss | |
$ | (4,439 | ) | |
$ | (11,005 | ) | |
$ | (31,347 | ) | |
$ | (21,617 | ) |
| Deemed dividend on Series A and Series A-1 Convertible Preferred Stock | |
| — | | |
| — | | |
| — | | |
| (7,496 | ) |
| Series B and Series B-1 Convertible Preferred Stock dividends earned | |
| (3,449 | ) | |
| — | | |
| (12,559 | ) | |
| — | |
| Net loss attributable to Lucid Diagnostics Inc. common stockholders | |
$ | (7,888 | ) | |
$ | (11,005 | ) | |
$ | (43,906 | ) | |
$ | (29,113 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Denominator | |
| | | |
| | | |
| | | |
| | |
| Weighted average common shares outstanding, basic and diluted | |
| 98,989,161 | | |
| 48,212,040 | | |
| 83,976,182 | | |
| 46,613,362 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss per share (1) | |
| | | |
| | | |
| | | |
| | |
| Net loss per share - basic and diluted | |
$ | (0.08 | ) | |
$ | (0.23 | ) | |
$ | (0.52 | ) | |
$ | (0.62 | ) |
| (1) | | - Convertible Preferred
Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However,
the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no
impact on the Company’s net loss per share calculation for the periods indicated. |
Basic
weighted-average number of shares of common stock outstanding for the six months ended June 30, 2025 and 2024 include the shares of the
Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares common
stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes
such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average
shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded
from the computation of diluted weighted average shares outstanding are as follows:
Schedule
of Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share
| | |
2025 | | |
2024 | |
| | |
June 30, | |
| | |
2025 | | |
2024 | |
| | |
| | |
| |
| Stock options | |
| 9,832,030 | | |
| 8,744,626 | |
| Unvested restricted stock awards | |
| 6,584,240 | | |
| 3,897,440 | |
| Preferred stock | |
| 49,607,115 | | |
| 51,682,378 | |
| Total | |
| 66,023,385 | | |
| 64,324,444 | |
|